Cervical Cancer
837 clinical trials
51 cell line models
7 approved drugs
Cervical Cancer
Molecular Synopsis
Drugs and clinical candidates

7 drugs have received FDA approval for Cervical Cancer:

  • Bevacizumab
  • Bleomycin Sulfate
  • Pembrolizumab
  • Recombinant Human Papillomavirus (HPV) Bivalent Vaccine
  • Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine

110 drugs have a clinical trial registered for Cervical Cancer.

3031 compounds have been tested in Cervical Cancer (1223 <= 500nM potency).

Sources: cancer.gov, clinicaltrials.gov, ChEMBL.

Clinical trials
There are 837 clinical trials for Cervical Cancer, 309 of which have one or more drug interventions, 528 with no drug intervention.
Cell line models

There are 51 Cell Line Models for Cervical Cancer.

Source: COSMIC
Cell line models

Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Cervical Cancer:
  • Uterine Cervical Neoplasms
The following terms have been mapped from cancer.gov to Cervical Cancer:
  • Cervical cancer that is recurrent or metastatic. It is used in patients whose cancer has the PD-L1 protein and whose disease got worse during or after chemotherapy.????
  • Cervical cancer that has not gotten better with other treatment, has metastasized (spread to other parts of the body), or has recurred (come back)
  • Squamous cell carcinoma of the cervix
  • Lesions that sometimes lead to anal, cervical, vaginal, or vulvar cancer
  • Cervical cancer that has not gotten better with other treatment or has recurred (come back). It is used with another drug, called cisplatin